ACSL4 is negatively correlated with the prognosis of HCC patients because it can stabilize the oncoprotein MYC proto-oncogene, BHLH transcription factor (MYC), in a mitogen-activated protein kinase (MAPK)/F-box and WD repeat domain containing 7 (FBXW7)-dependent manner via the ubiquitin-proteasome system, thus promoting cancer cell growth [79]. This evidence concerns the gene ACSL4 and cancer.